XNASHOOK
Market cap17mUSD
Jan 14, Last price
1.86USD
1D
4.49%
1Q
-52.31%
IPO
-86.71%
Name
HOOKIPA Pharma Inc
Chart & Performance
P/E
—
P/S
0.89
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-10.35%
Rev. gr., 5y
21.41%
Revenues
20m
+41.27%
Net income
-82m
L+25.67%
CFO
-58m
L+187.66%
Earnings
Mar 20, 2025
Profile
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 20,129 41.27% | 14,249 -22.76% | |||||
Cost of revenue | 108,609 | 91,006 | |||||
Unusual Expense (Income) | |||||||
NOPBT | (88,480) | (76,757) | |||||
NOPBT Margin | |||||||
Operating Taxes | 368 | 230 | |||||
Tax Rate | |||||||
NOPAT | (88,848) | (76,987) | |||||
Net income | (81,580) 25.67% | (64,915) -14.21% | |||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 49,043 | 75,121 | |||||
BB yield | -640.53% | -1,414.38% | |||||
| Debt | |||||||
Debt current | 4,396 | 3,282 | |||||
Long-term debt | 9,240 | 7,219 | |||||
Deferred revenue | 19,674 | 25,664 | |||||
Other long-term liabilities | 6,017 | 3,420 | |||||
Net debt | (103,460) | (103,362) | |||||
| Cash flow | |||||||
Cash from operating activities | (57,524) | (19,997) | |||||
CAPEX | (4,159) | (5,017) | |||||
Cash from investing activities | (4,159) | (5,017) | |||||
Cash from financing activities | 65,670 | 72,271 | |||||
FCF | (78,685) | (66,186) | |||||
| Balance | |||||||
Cash | 117,096 | 113,444 | |||||
Long term investments | 419 | ||||||
Excess cash | 116,090 | 113,151 | |||||
Stockholders' equity | (377,184) | (294,832) | |||||
Invested Capital | 496,550 | 432,706 | |||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 9,453 | 6,557 | |||||
Price | 0.81 0.00% | 0.81 -65.24% | |||||
Market cap | 7,657 44.16% | 5,311 -30.71% | |||||
EV | (95,803) | (98,051) | |||||
EBITDA | (84,928) | (73,155) | |||||
EV/EBITDA | 1.13 | 1.34 | |||||
Interest | 317 | 687 | |||||
Interest/NOPBT | |||||||